Germany: Zambon to buy Breath Therapeutics for €140m

Roberto Tascione, chief executive officer, Zambon

Privately held Italian pharmaceutical firm Zambon is to purchase Munich-based drug device platform Breath Therapeutics from European venture capital firm Sofinnova Partners for €140m (US$156m). Subject to regulatory and sales milestones, the price could rise to €500m. Sofinnova Partners is exiting Breath Therapeutics after two and a half years. It co-led Breath Therapeutics’ €43.5 million Series…

You must be a HMI Subscriber to view this content.

Subscribe Now »